α-Synuclein in CSF of patients with severe traumatic brain injury

Stefania Mondello, A. Büki, Domenico Italiano, Andreas Jeromin

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: The study aims to examine α-synuclein in the CSF of patients with severe traumatic brain injury (TBI) and its relationship with clinical characteristics and long-term outcomes. Methods: This prospective case-control study enrolled patients with severe TBI (Glasgow Coma Score ≤8) who underwent ventriculostomy. CSF samples were taken from each TBI patient at admission and daily for up to 8 days after injury and successively assessed by ELISA. Control CSF was collected for analysis from subjects receiving lumbar puncture for other medical reasons. We used trajectory analysis to identify distinct temporal profiles of CSF α-synuclein that were compared with clinical outcomes. Results: CSF α-synuclein was elevated in TBI patients after injury as compared to controls (p = 0.0008). Overall, patients who died had higher concentrations (area under the curve) over 8 days of observation compared to those who survived at 6 months postinjury (p = 0.002). Two distinct temporal α-synuclein profiles were recognized over time. Subjects who died had consistently elevated α-synuclein levels compared to those who survived with α-synuclein levels near controls. High-risk trajectory was a strong and accurate predictor of death with 100%specificity and a very high sensitivity (83%). Conclusions: Taken together, these data support the hypothesis that in severe TBI patients, substantial increase of CSF α-synuclein may indicate widespread neurodegeneration and reflect secondary neuropathologic events occurring after injury. The determination of CSF α-synuclein may be a valuable prognostic marker, adding to the clinical assessment and creating opportunities for medical intervention.

Original languageEnglish
Pages (from-to)1662-1668
Number of pages7
JournalNeurology
Volume80
Issue number18
DOIs
Publication statusPublished - Apr 30 2013

Fingerprint

Synucleins
Wounds and Injuries
Ventriculostomy
Spinal Puncture
Traumatic Brain Injury
Patient Admission
Coma
Area Under Curve
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Observation

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

α-Synuclein in CSF of patients with severe traumatic brain injury. / Mondello, Stefania; Büki, A.; Italiano, Domenico; Jeromin, Andreas.

In: Neurology, Vol. 80, No. 18, 30.04.2013, p. 1662-1668.

Research output: Contribution to journalArticle

Mondello, Stefania ; Büki, A. ; Italiano, Domenico ; Jeromin, Andreas. / α-Synuclein in CSF of patients with severe traumatic brain injury. In: Neurology. 2013 ; Vol. 80, No. 18. pp. 1662-1668.
@article{d14e968038da4ea6a88d4ea49a2cf4e8,
title = "α-Synuclein in CSF of patients with severe traumatic brain injury",
abstract = "Objective: The study aims to examine α-synuclein in the CSF of patients with severe traumatic brain injury (TBI) and its relationship with clinical characteristics and long-term outcomes. Methods: This prospective case-control study enrolled patients with severe TBI (Glasgow Coma Score ≤8) who underwent ventriculostomy. CSF samples were taken from each TBI patient at admission and daily for up to 8 days after injury and successively assessed by ELISA. Control CSF was collected for analysis from subjects receiving lumbar puncture for other medical reasons. We used trajectory analysis to identify distinct temporal profiles of CSF α-synuclein that were compared with clinical outcomes. Results: CSF α-synuclein was elevated in TBI patients after injury as compared to controls (p = 0.0008). Overall, patients who died had higher concentrations (area under the curve) over 8 days of observation compared to those who survived at 6 months postinjury (p = 0.002). Two distinct temporal α-synuclein profiles were recognized over time. Subjects who died had consistently elevated α-synuclein levels compared to those who survived with α-synuclein levels near controls. High-risk trajectory was a strong and accurate predictor of death with 100{\%}specificity and a very high sensitivity (83{\%}). Conclusions: Taken together, these data support the hypothesis that in severe TBI patients, substantial increase of CSF α-synuclein may indicate widespread neurodegeneration and reflect secondary neuropathologic events occurring after injury. The determination of CSF α-synuclein may be a valuable prognostic marker, adding to the clinical assessment and creating opportunities for medical intervention.",
author = "Stefania Mondello and A. B{\"u}ki and Domenico Italiano and Andreas Jeromin",
year = "2013",
month = "4",
day = "30",
doi = "10.1212/WNL.0b013e3182904d43",
language = "English",
volume = "80",
pages = "1662--1668",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - α-Synuclein in CSF of patients with severe traumatic brain injury

AU - Mondello, Stefania

AU - Büki, A.

AU - Italiano, Domenico

AU - Jeromin, Andreas

PY - 2013/4/30

Y1 - 2013/4/30

N2 - Objective: The study aims to examine α-synuclein in the CSF of patients with severe traumatic brain injury (TBI) and its relationship with clinical characteristics and long-term outcomes. Methods: This prospective case-control study enrolled patients with severe TBI (Glasgow Coma Score ≤8) who underwent ventriculostomy. CSF samples were taken from each TBI patient at admission and daily for up to 8 days after injury and successively assessed by ELISA. Control CSF was collected for analysis from subjects receiving lumbar puncture for other medical reasons. We used trajectory analysis to identify distinct temporal profiles of CSF α-synuclein that were compared with clinical outcomes. Results: CSF α-synuclein was elevated in TBI patients after injury as compared to controls (p = 0.0008). Overall, patients who died had higher concentrations (area under the curve) over 8 days of observation compared to those who survived at 6 months postinjury (p = 0.002). Two distinct temporal α-synuclein profiles were recognized over time. Subjects who died had consistently elevated α-synuclein levels compared to those who survived with α-synuclein levels near controls. High-risk trajectory was a strong and accurate predictor of death with 100%specificity and a very high sensitivity (83%). Conclusions: Taken together, these data support the hypothesis that in severe TBI patients, substantial increase of CSF α-synuclein may indicate widespread neurodegeneration and reflect secondary neuropathologic events occurring after injury. The determination of CSF α-synuclein may be a valuable prognostic marker, adding to the clinical assessment and creating opportunities for medical intervention.

AB - Objective: The study aims to examine α-synuclein in the CSF of patients with severe traumatic brain injury (TBI) and its relationship with clinical characteristics and long-term outcomes. Methods: This prospective case-control study enrolled patients with severe TBI (Glasgow Coma Score ≤8) who underwent ventriculostomy. CSF samples were taken from each TBI patient at admission and daily for up to 8 days after injury and successively assessed by ELISA. Control CSF was collected for analysis from subjects receiving lumbar puncture for other medical reasons. We used trajectory analysis to identify distinct temporal profiles of CSF α-synuclein that were compared with clinical outcomes. Results: CSF α-synuclein was elevated in TBI patients after injury as compared to controls (p = 0.0008). Overall, patients who died had higher concentrations (area under the curve) over 8 days of observation compared to those who survived at 6 months postinjury (p = 0.002). Two distinct temporal α-synuclein profiles were recognized over time. Subjects who died had consistently elevated α-synuclein levels compared to those who survived with α-synuclein levels near controls. High-risk trajectory was a strong and accurate predictor of death with 100%specificity and a very high sensitivity (83%). Conclusions: Taken together, these data support the hypothesis that in severe TBI patients, substantial increase of CSF α-synuclein may indicate widespread neurodegeneration and reflect secondary neuropathologic events occurring after injury. The determination of CSF α-synuclein may be a valuable prognostic marker, adding to the clinical assessment and creating opportunities for medical intervention.

UR - http://www.scopus.com/inward/record.url?scp=84879072693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879072693&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3182904d43

DO - 10.1212/WNL.0b013e3182904d43

M3 - Article

C2 - 23553480

AN - SCOPUS:84879072693

VL - 80

SP - 1662

EP - 1668

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 18

ER -